Drug Trial Radar · NCT02200770
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
Last checked: Nov 20, 2026Latest source record: Dec 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
231
Actual
Start
Apr 1, 2015
Primary completion
Oct 26, 2018
Study completion Nov 6, 2020
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.
Conditions
- Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Interventions
InebilizumabDrug
Participants will receive IV inebilizumab 300 mg.
PlaceboOther
Participants will receive IV placebo matched to inebilizumab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCPTime frame: Day 1 (Baseline) through Day 197
Locations
98 sites in 25 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Sacramento, California
Research Site
San Francisco, California
Research Site
Aurora, Colorado
Research Site
New Haven, Connecticut
Research Site
Maitland, Florida
Research Site
Chicago, Illinois
Research Site
Kansas City, Kansas
Research Site
Baltimore, Maryland
Research Site
Detroit, Michigan
Research Site
Rochester, Minnesota
Research Site
St Louis, Missouri
Research Site
Raleigh, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Cleveland, Ohio
Research Site
Mansfield, Ohio
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Richmond, Virginia
Research Site
Melbourne, Australia
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Vancouver, British Columbia, Canada
Research Site
Barranquilla, Colombia
Research Site
Bogotá, Colombia
Research Site
Bogotá, Colombia
Research Site
Cali, Colombia
Research Site
Olomouc, Czechia
Research Site
Prague, Czechia
Research Site
Teplice, Czechia
Research Site
Tallinn, Estonia
Research Site
Tartu, Estonia
Research Site
Berlin, Germany
Research Site
Dresden, Germany
Research Site
Düsseldorf, Germany
Research Site
Leipzig, Germany
Research Site
Münster, Germany
Research Site
Rostock, Germany
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.